Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Viridian Therapeutics, Inc.\DE

NASDAQ: VRDN · Life Sciences · 4 alerts · CIK 1590750

Share price
$29.80Close, Nov 16
Market cap
$3.38B
Shares outstanding
113.56MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Viridian Therapeutics, Inc.\DE filings on SEC EDGAR ↗

7:33 AM ET 8-K
Clinical Trial Data

Viridian Therapeutics, Inc.\DE Clinical Trial Data

Viridian Therapeutics announced positive Phase 1 clinical trial results for VRDN-008, a half-life extended FcRn inhibitor, which demonstrated a 74% peak reduction in IgG and a half-life 5-6 times longer than first-generation fragments. The data supports a potential best-in-class every-eight-week subcutaneous dosing regimen, and the company plans to initiate a pivotal trial in myasthenia gravis in mid-2027.

7:30 AM ET 10-Q
Financial Results ▶ Call

Viridian Therapeutics, Inc.\DE Q3 2026 Results: Net Loss of $101M, Loss Widens

Viridian Therapeutics is transitioning toward commercialization with the submission of a Marketing Authorization Application for veligrotug in Europe and a planned BLA submission for elegrobart in early 2027. The company remains pre-profit, relying on existing cash and anticipated future revenues to fund its clinical pipeline, including new trials for VRDN-292 and its FcRn inhibitor portfolio.

Key figure
Net loss $101M
7:12 AM ET 8-K
Financial Results

Viridian Therapeutics, Inc.\DE Financial Results

Viridian Therapeutics reported third quarter 2026 financial results, highlighted by $24.7 million in net product revenue from the launch of Lumvoa (veligrotug-vvze). The company remains on track for a BLA submission for elegrobart in Q1 2027 and expects Phase 1 data for VRDN-008 in Q4 2026.

“We are highly encouraged by the strength of Lumvoa’s early launch in TED, which has exceeded expectations. These strong early results are a testament to Lumvoa’s compelling clinical profile, the extraordinary execution of our Commercial and Medical teams, and the incredible support of our broader organization.”

Steve Mahoney, President and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.